Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) ROE % Adjusted to Book Value : Negative Equity% (As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings ROE % Adjusted to Book Value?

Parnell Pharmaceuticals Holdings's ROE % for the quarter that ended in Dec. 2018 was Negative Equity. Parnell Pharmaceuticals Holdings's PB Ratio for the quarter that ended in Dec. 2018 was N/A. Parnell Pharmaceuticals Holdings's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2018 was Negative Equity.

Parnell Pharmaceuticals Holdings ROE % Adjusted to Book Value Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings ROE % Adjusted to Book Value Chart

Parnell Pharmaceuticals Holdings Annual Data

Trend

Jun12

Jun13

Jun14

Dec15

Dec16

Dec17

Dec18

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-33.26

-11.55

-73.33

Negative Equity

Parnell Pharmaceuticals Holdings Semi-Annual Data
	Jun12	Jun13	Jun14	Dec15	Dec16	Dec17	Dec18
ROE % Adjusted to Book Value	Get a 7-Day Free Trial			-17.72	-11.55	-73.33	-	Negative Equity

Competitive Comparison of Parnell Pharmaceuticals Holdings's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parnell Pharmaceuticals Holdings's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's ROE % Adjusted to Book Value falls into.

Parnell Pharmaceuticals Holdings ROE % Adjusted to Book Value Calculation

Parnell Pharmaceuticals Holdings's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2018 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	Negative Equity	/	N/A
	=	Negative Equity

Parnell Pharmaceuticals Holdings's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2018 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	Negative Equity	/	N/A
	=	Negative Equity

Parnell Pharmaceuticals Holdings ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015

Website

https://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.